InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director
InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors. In addition to his board responsibilities, Dr. Levick will provide scientific and clinical development guidance to the board and management as the company advances its pipeline towards clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries. Mark’s expertise was gained through a 25+ year international career leading global research and development groups as Global Head of Development at Sandoz Biopharmaceuticals; Senior Vice President, Global Drug Discovery at Novartis; and Vice-President, Biopharmaceutical Translational Medicine at GSK. Mark oversaw R&D programs that resulted in thirteen drug approvals, including five first-in-class molecules and two approvals arising from successful human proof-of-concept programs. Before joining the industry, Mark was a medical reviewer for the UK and EU medicines regulatory authorities, and a specialist physician-scientist practicing in university hospitals in Australia and the UK. As a researcher at Cambridge University, Mark pioneered the use of reverse genetics to identify novel vaccine targets as well as conducting amongst the earliest in vivo studies using nucleic acid as a novel vaccine platform. Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development. He is a fellow of the Royal College of Pathologists of Australasia (FRCPA), an affiliate physician with the Faculty of Pharmaceutical Medicine in the Royal College of Physicians, UK, and an advisor to the Commonwealth Scholarship Commission. Mark holds a Doctor of Medicine from University of Newcastle, Australia and a PhD from the University of Cambridge.
“Mark brings an extraordinary breadth and depth of experience in drug development to InterAx at a time when we are preparing to advance our pipeline to clinical trials”, noted Dr. Prior, InterAx CEO. “Mark’s scope of experience extends from early preclinical and translational medicine studies to support first-in-human trials all way to approval and the commercial process,” Dr. Prior added.
“I am very attracted to the InterAx drug discovery platform that deciphers the intracellular language that drives biological responses and applying this understanding to create truly novel therapies,” commented Dr. Levick. “I believe InterAx represents the future of drug development and with the aid of AI integrated into biological, biochemical and pharmacological data, this approach promises to reduce conventional timelines for drug development by years,” Dr. Levick added.
Dr. Rizk, InterAx CSO, added, “Dr. Levick brings a tremendous dimension of experience as we discover and develop small, orally-administered molecules with dual functions for treating diseases in a highly novel manner, starting with our cancer and inflammation programs. We are eager to work with Dr. Levick on our development plans, especially given his knowledge of the use of biomarkers as predictors of halting progression of disease.”
InterAx Biotech AG
The company, a spin-out from ETH Zurich and the Paul Scherrer Institute in Switzerland, developed an integrated drug discovery process combining biochemical compound screening, cell pathways mathematical modeling, and artificial intelligence based chemical structure to function relationship. This unique approach enables the rapid and precise identification of novel cellular mechanisms to develop differentiated products that stand out for their effectiveness and safety profiles. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks.
The company is specialized in G Protein-Coupled Receptor (GPCR) drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan GPCRs. InterAx has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry. The company is currently funded by lead institutional investors and a grant from the EU commission and is preparing for the next round of financing to grow its capabilities and advance lead drug candidates.
For more information, please visit linkedin.com/company/interax-biotech | www.interaxbiotech.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231003682932/en/
Contact information
Media: Luca Zenone, contact@interaxbiotech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARAMIS Global Ambassador, Dwyane Wade, Celebrates New Fragrance Launch During New York Fashion Week13.9.2025 20:13:00 EEST | Press release
Heritage men’s fragrance brand, ARAMIS, officially launched its new scent, Intuition, with global ambassador, Dwyane Wade, during New York Fashion Week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250913048158/en/ ARAMIS Global Ambassador, Dwyane Wade, attends Brand’s NYFW Pop-Up at The High Line (Courtesy of BFA ) The celebration kicked off with an immersive pop-up on New York City’s iconic High Line, where guests explored the story behind the fragrance through scent, sound, and design. Dwyane Wade made a personal appearance at the interactive event, joined by his wife, actress Gabrielle Union. Later in the afternoon, Wade participated in an intimate conversation around personal grooming, fragrance, and modern masculinity at Bloomingdale's 59th Street. Moderated by Mike Muse, the conversation also featured Donato Smith, Wade's longtime barber, and friend. Bloomingdale’s top clients were given the opportunity to connect i
SUI Group Announces Completion of Existing $2 Million Stock Repurchase Program and Subsequent Authorization of New $50 Million Program12.9.2025 23:05:00 EEST | Press release
SUI Group Holdings Limited (“SUI Group,” “SUIG” or the “Company”) (NASDAQ: SUIG), the only publicly traded company with an official relationship with the Sui Foundation, today announced it has completed its previously authorized $2 million stock repurchase program. SUI Group is also announcing that its Board of Directors has now authorized a new stock repurchase program to acquire up to an additional $50 million of the Company’s common stock. Following the completion of its initial stock repurchase program, in which the Company repurchased approximately 318,743 shares of its common stock at an average price of $4.30 per share between September 10, 2025 and September 12, 2025, SUI Group’s new program provides the flexibility to support its Net Asset Value (“NAV”) per share by opportunistically purchasing its common stock. The Company believes that share repurchases at these levels are immediately accretive to existing stockholders and reflects its confidence in its underlying fundamenta
Allied Nations Gather to Discuss Future of Multilateral Defence Security Financing12.9.2025 18:35:00 EEST | Press release
The Defence, Security and Resilience Bank (DSRB) Development Group co-hosted an international conference in the City of London this week to discuss the creation of a new multilateral bank designed to bring capital market expertise to the frontlines of global security. The event at Mansion House, co-hosted by the Lord Mayor of London, included 72 attendees from 37 countries across the NATO alliance, the EU, and Indo-Pacific allied nations. Held on the eve of the Defence and Security Equipment International (DSEI event), the DSRB “Information Day” event also included a further 88 attendees from a wide range of institutions including the European Union, NATO, eight partner commercial banks, multiple development and central banks as well as representatives from global funds, ratings agencies, industry associations and think tanks. Notes to Editors: The DSR Bank Development Group is a non-profit working toward the establishment of the full bank alongside nation states and institutions. The
Illumination and Nintendo Announce the New Animated Film Based on the World of Super Mario Bros. Will Be Titled The Super Mario Galaxy Movie12.9.2025 16:33:00 EEST | Press release
Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that the title of the new animated film based on the world of Super Mario Bros., will be The Super Mario Galaxy Movie. The film will be released worldwide by Universal Pictures beginning April 3, 2026. In addition, the two companies announced that the returning voice actors for the characters will be: Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), and Kamek (Kevin Michael Richardson). The additional characters and voice cast for The Super Mario Galaxy Movie will be announced at a later date. The Super Mario Galaxy Movie will be released on April 3, 2026 in the US and many additional markets globally, and will be released on April 24, 2026 in Japan, with select territories releasing through
TON Strategy Company Announces Initial Share Repurchases Under $250 Million Program, Buying Below Treasury Asset Value Per Share, and Start of Staking12.9.2025 15:30:00 EEST | Press release
TON Strategy Company (Nasdaq: TONX) (the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today announced that it has repurchased over 250,000 shares of its common stock under its previously announced $250 million share repurchase program. Further, the Company has started staking operations, as planned, to generate on-chain income by utilizing its treasury holdings. The Company repurchased shares at an average of $8.32 per share; by comparison, the Company’s TAV per share was $12.181 as of September 11, 2025. This week’s share repurchases and the start of staking underscore TON Strategy Company’s financial strength, commitment to shareholder value, and long-term confidence in The Open Network (TON) ecosystem. They coincide with recent milestones in the broader TON network – including the availability of $TON on Gemini, Robinhood, and Zengo – which the Company believes represent steps toward broader market access for the token as the native asset of TON,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom